{"schema_version":"secwatch.filing_event.v1","accession":"0001370053-23-000005","form_type":"8-K","ticker":"ANAB","cik":"0001370053","company_name":"ANAPTYSBIO, INC","filed_at":"2023-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.651326+00:00","generated_at":"2026-06-20T19:27:58.089568+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AnaptysBio ends alopecia areata trial; launches Phase 2b for RA and atopic dermatitis","bullets":["Rosnilimab Phase 2a in alopecia areata failed to achieve target efficacy (no patient SALT<20); further development discontinued.","Advancing rosnilimab (PD-1 agonist) into global Phase 2b for rheumatoid arthritis; initiates Q3 2023, top-line mid-2025.","Advancing ANB032 (BTLA agonist) into global Phase 2b for atopic dermatitis; initiates Q2 2023, top-line year-end 2024.","Cash and investments >$575M as of Dec 31, 2022; estimated ~4-year runway excluding GSK royalties.","Rosnilimab second Phase 2 trial in undisclosed indication expected by year-end 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001370053-23-000005","json":"https://secwatch.observer/filing/0001370053-23-000005.json","markdown":"https://secwatch.observer/filing/0001370053-23-000005.md","text":"https://secwatch.observer/filing/0001370053-23-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370053/000137005323000005/0001370053-23-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370053/000137005323000005/anab-20230105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T19:27:58.089568+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}